vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) granted 4,000 stock options to a non-executive employee as a material inducement under Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $39.54 (closing price on April 6, 2026), 10-year term, and vest over four years (25% at one year, then quarterly over 36 months), subject to the 2026 Inducement Plan and the stock option agreement.

News Market Reaction – VTVT

+0.55%

6 alerts

+0.55% Session close to close

$144.40M Market Cap

0.9x Rel. Volume

In the Apr 8 session, VTVT gained 0.55%, reflecting a mild positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a routine inducement equity grant of 4,000 stock options at an exercise pr...

Analysis

This announcement details a routine inducement equity grant of 4,000 stock options at an exercise price of $39.54, vesting over a four-year schedule under the 2026 Inducement Plan. It follows a series of more material updates on licensing, cash runway, and Phase 3 progress for cadisegliatin. Investors may focus less on this HR-driven grant and more on upcoming clinical milestones and the company’s capacity, through its effective S-3 shelf, to fund development activities.

Key Figures

Inducement stock options: 4,000 options Option exercise price: $39.54 per share Vesting period: 4 years +3 more

6 metrics

Inducement stock options 4,000 options Grant to a non-executive employee as inducement to employment

Option exercise price $39.54 per share Equal to closing price of common stock on April 6, 2026

Vesting period 4 years Employee stock options vest over four years, service-based

Initial vesting cliff 25% after 1 year 25% vests on first anniversary of vesting commencement date

Subsequent vesting Quarterly over 36 months Remaining 75% vests quarterly over following 36 months

Option term 10 years Expiration term of the inducement stock options

Historical Context

5 past events · Latest: Mar 16 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 16	Conference participation	Neutral	+7.4%	Announcement of participation in the 38th Annual ROTH investor conference.
Mar 10	Earnings and update	Positive	+0.2%	Q4 and 2025 results plus cash position and Phase 3 CATT1 enrollment timeline.
Feb 13	Investor conferences	Neutral	-7.2%	Planned participation in Oppenheimer and TD Cowen healthcare conferences.
Feb 02	License amendment	Positive	+8.2%	Expanded global license of HPP737 to Newsoara with upfront, milestones and royalties.
Dec 18	Clinical protocol	Positive	+3.7%	Submission of a Phase 2 cadisegliatin protocol for T2D in UAE and partners.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent price reactions to corporate and clinical news skew positive, with one notable selloff on neutral conference participation.

Recent Company History

Over the last several months, vTv has reported multiple corporate and clinical milestones. A Newsoara license amendment on Feb 2, 2026 and a cadisegliatin Phase 2 protocol submission on Dec 18, 2025 both coincided with positive price reactions. Financial updates on Mar 10, 2026 produced a flat response, while conference participation headlines in February and March saw mixed moves, including a -7.18% drop. Against this backdrop, the current small inducement option grant under Nasdaq rules fits as routine corporate housekeeping rather than a major catalyst.

Key Terms

nasdaq listing rule 5635(c)(4), stock options, exercise price, vesting, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"it granted 4,000 stock options to purchase shares of common stock"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The stock options that were granted have an exercise price of $39.54 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Each option will vest over a 4-year period, with 25% of the shares underlying"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

inducement plan financial

"subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 4,000 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise price of $39.54 per share, which is equal to the closing price of the Company’s common stock on April 6, 2026. Each option will vest over a 4-year period, with 25% of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to the employee’s continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

What inducement did vTv Therapeutics (VTVT) announce on April 7, 2026?

vTv granted 4,000 stock options to a non-executive employee as an inducement grant. According to vTv Therapeutics, the grant is under Nasdaq Listing Rule 5635(c)(4) and is intended as a material inducement to employment.

What is the exercise price and effective date for VTVT inducement options?

The options have an exercise price of $39.54, equal to the closing price on April 6, 2026. According to vTv Therapeutics, that closing price sets the strike and the options carry a 10-year term from grant.

How do the VTVT inducement options vest and what is the term?

The options vest over four years: 25% at the one-year anniversary, then quarterly over 36 months. According to vTv Therapeutics, the options have a 10-year contractual term and are subject to plan terms.

Who received the inducement options and under which Nasdaq rule for VTVT?

A non-executive employee received the 4,000-option inducement grant. According to vTv Therapeutics, the award complies with Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.